Theclinical study DeOvo, Investigational Proprietary Drug, New topical treatment for head lice infestationHatchtech Pty Ltd confirms a successful Phase IIa clinical trial evaluating DeOvo with developed an investigational proprietary drug development as a novel topical treatment for head lice infestation. The double-blind placebo-controlled study in 30 in 30 heavily infected adult subjects. It was designed primarily the safety profile the safety profile of the product after a single 10-20 minute application to the hair and scalp. An analysis of the data determined that DeOvo is safe and well tolerated..
Wheelock, Justus Bayarugaba, Fred Kironde, Thomas G Qijun Chen, Bj rn Andersson and Mats Wahlgren PNAS Online Early Edition, 24-28 September 2007?. ###The study is a collaboration between Karolinska Institutet, the Swedish Institute for Infectious Diseases, Makerere University and Medical Biotech Laboratories in Uganda, and was for the Swedish Agency international Development Cooperation Agency has been by the Swedish by the Swedish Research Council and the EU publication ‘ ‘PfEMP1 – DBL1a amino acid motifs in severe disease states of Plasmodium falciparum malaria’, Johan Normark, Daniel Nilsson, Ulf Ribacke, Gerhard Winter, Kirsten Moll,.Weak health systems be one of the greatest obstacles to the expansion of the immunization and any other life-saving interventions and is a key obstacle to the attainment of the MDG, in particular objective 4 and 5 who want to reduce child and maternal death. – ‘A large part of the the world disease burden may prevented or cured time be is famous, can not afford technologies order to achieve this the problem is always that drugs, vaccines and other forms of prevention, support or treating on the they need.